Santhera Pharmaceuticals Holding AG (SPHDF)
Sector: Biotechnology
Industry: Biotechnology
Santhera Pharmaceuticals Holding AG
OTC:SPHDFHealthcare · Medical - Pharmaceuticals
CLOSED
Mkt Cap$280.12M
EV-
Float10.98M
O/S15.31M
VOL110 sh
$ Vol$2K
Inst Own-
SI1.5%
Net Cash/Sh-
EarningsApr 29 · in 5mo
Dilution
MCap$280.12MFloat10.98MO/S15.31M
Dilution
Historical Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 16, 2026 | 22.85 | 22.85 | 18.30 | 18.30 | 100 |
| Nov 13, 2026 | 18.30 | 18.30 | 18.30 | 18.30 | 100 |
| Nov 12, 2026 | 18.30 | 18.30 | 18.30 | 18.30 | 100 |
| Nov 11, 2026 | 18.30 | 18.30 | 18.30 | 18.30 | 100 |
| Nov 10, 2026 | 18.30 | 18.30 | 18.30 | 18.30 | 100 |
| Nov 9, 2026 | 18.30 | 18.30 | 18.30 | 18.30 | 100 |
| Nov 6, 2026 | 18.30 | 18.30 | 18.30 | 18.30 | 100 |
| Nov 5, 2026 | 18.30 | 18.30 | 18.30 | 18.30 | 100 |
| Nov 4, 2026 | 18.30 | 18.30 | 18.30 | 18.30 | 100 |
| Nov 3, 2026 | 18.30 | 18.30 | 18.30 | 18.30 | 100 |
| Oct 30, 2026 | 18.30 | 18.30 | 18.30 | 18.30 | 100 |
| Oct 29, 2026 | 18.30 | 18.30 | 18.30 | 18.30 | 100 |
| Oct 28, 2026 | 18.30 | 18.30 | 18.30 | 18.30 | 100 |
| Oct 27, 2026 | 18.30 | 18.30 | 18.30 | 18.30 | 100 |
| Oct 26, 2026 | 18.30 | 18.30 | 18.30 | 18.30 | 100 |
| Oct 23, 2026 | 18.30 | 18.30 | 18.30 | 18.30 | 100 |
| Oct 21, 2026 | 18.30 | 18.30 | 18.30 | 18.30 | 100 |
| Oct 20, 2026 | 18.30 | 18.30 | 18.30 | 18.30 | 100 |
| Oct 19, 2026 | 18.30 | 18.30 | 18.30 | 18.30 | 100 |
| Oct 16, 2026 | 18.30 | 18.30 | 18.30 | 18.30 | 100 |
Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
About
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia.
The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy.
Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Key Metrics
Market Cap$280.12M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--
based on 15.31M shares outstanding
SectorHealthcare
IndustryMedical - Pharmaceuticals
ExchangeOTC
Country
CH
IPO DateApr 17, 2014
Shares Outstanding15.31M
Authorized Shares
Float10.98M
52-Week Range
Volume
Average Daily Volume--
30d Avg
--
60d Avg
110
90d Avg
355
Earnings
Dividend History
No dividend history available